What Recarbrio Treats: Main Uses and Benefits

Recarbrio is a specialized antibacterial combination commonly used for managing serious infections caused by specific susceptible Gram-negative bacteria in adults. Its use is generally considered relevant in situations where patients may have limited or no other effective supportive options, addressing the challenge of antibiotic resistance. The drug is applied across therapeutic areas that represent complex and severe conditions where immediate and effective symptomatic management is important. Its use is considered relevant in clinical contexts involving heightened systemic burden.

Therapeutic Focus and Benefit

The drug plays a role in managing severe infections acquired in the hospital setting, such as Hospital-Acquired Bacterial Pneumonia (HABP) and Complicated Intra-abdominal Infections (cIAI), along with Ventilator-Associated Bacterial Pneumonia (VABP) and Complicated Urinary Tract Infections (cUTI). By addressing the infection, it contributes to easing the overall symptom load related to severe systemic imbalance, assisting with symptoms related to physical discomfort, and supports the patient's ability to achieve a favorable clinical response during complex episodes. This provides a therapeutic choice for managing pathogens that create noticeable physiological strain.

Quick Fact: Relief for Symptoms Related to Systemic Imbalance

Eligibility Map: Who Can and Cannot Use Recarbrio

Official regulatory documents define patient eligibility for Recarbrio based on hypersensitivity, age, and renal function. This medicine is contraindicated in patients with a history of known severe allergic reactions (hypersensitivity) to any of its components or to other beta-lactam antibacterial agents, such as carbapenems or penicillins.

Eligibility is limited primarily to the adult population. Conditional use is required for patients with compromised kidney function, and an absolute exclusion applies to individuals with a history of specific severe drug allergies.

Recarbrio Interactions with other medicines and products

The interaction profile for Recarbrio (Imipenem, Cilastatin, and Relebactam) details specific drug-drug combinations that carry regulatory warnings, primarily concerning the central nervous system (CNS) and drug exposure.

Formally Documented Interactions

Interaction Context and Restrictions

Regulatory authorities advise considering alternative antibacterial drugs for patients whose seizures are well-controlled on valproic acid or divalproex sodium. The increased risk of CNS adverse reactions, including the seizure risk from interactions, is noted to be more common in patients with compromised renal function and CNS disorders. No known interactions with food, alcohol, supplements, or herbal products that require label-based restrictions are documented in official prescribing information.

Core Mechanistic Domain: Disrupting Bacterial Cell Wall Synthesis

The primary antibacterial mechanism relies on the core antibiotic, Imipenem, which acts as an inhibitor of bacterial Penicillin-Binding Proteins (PBPs). By covalently binding to these essential enzymes, Imipenem blocks the final cross-linking step of peptidoglycan synthesis, which is critical for maintaining the bacterial cell wall's structure. This targeted interference leads to the structural collapse and lysis of susceptible bacteria, resulting in a bactericidal effect.

Mechanistic Synergy: Neutralizing Bacterial and Human Defense

Recarbrio’s action is supported by two protective components that preserve Imipenem's activity against otherwise resistant strains. Relebactam neutralizes key bacterial defense enzymes (Ambler Class A and C beta-lactamases), ensuring that Imipenem is not chemically destroyed before it reaches its PBP target. Concurrently, Cilastatin inhibits the human renal enzyme Dehydropeptidase-I (DHP-I), which prevents the metabolic breakdown of Imipenem within the kidney. This synergistic, three-part mechanism maintains effective levels of the active antibiotic, allowing the bactericidal activity to be expressed against strains producing susceptible enzymes.

How Recarbrio is Used: Official Administration Patterns

The principles governing the use of Recarbrio focus on its intravenous (IV) route and specific dosing adjustments based on a patient’s renal function. Usage parameters follow specific protocols for administration and preparation.

Administration Route, Preparation, and Timing

Recarbrio is supplied as a sterile powder for solution for infusion and is administered exclusively via the intravenous (IV) route. Administration is performed after the powder is constituted and subsequently diluted using aseptic technique with specific compatible diluents, such as 0.9% Sodium Chloride or 5% Dextrose injections. Each prepared dose is delivered as an intravenous infusion over 30 minutes for all approved regimens.

Standard Adult Dosing and Frequency

The standard adult dose is a fixed-dose combination of 1.25 grams (imipenem 500 mg / cilastatin 500 mg / relebactam 250 mg) for patients with normal kidney function, defined as a creatinine clearance (CLcr) of 90 mL/min or greater. This standard dose is administered every six hours (q6hr). The total recommended duration of treatment is generally between 4 days and 14 days, guided by the specific infection being treated.

Population-Specific Dosing

The primary factor determining dosage modification is the patient's renal function. Dose reduction is required for adult patients with reduced creatinine clearance, as the drug components are primarily cleared through the kidneys. Patients with End-Stage Renal Disease (ESRD) on hemodialysis receive a reduced dose of 0.5 grams every 6 hours, which is timed to follow the hemodialysis session. No specific dose adjustment is required solely on the basis of advanced age or impaired hepatic function. The safety and efficacy in patients below 18 years of age have not been established.

Research Evidence / Overview of Studies for Recarbrio

Recarbrio has been studied in research exploring severe bacterial infections caused by Gram-negative bacteria. The evidence is derived from randomized controlled trials (RCTs) and smaller, descriptive studies, all conducted within strict research protocols.

Evidence for Use in Severe Pneumonia (HABP and VABP)

The evidence for Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia (HABP/VABP) relies on randomized controlled trials comparing Recarbrio to other established antibiotic combinations. These studies examined patient survival status over an intermediate period of up to Day 28 and measured clinical response. The trial design was structured to examine patterns related to the non-inferiority margin when compared to the reference drug. Long-term effects are not fully established, as follow-up durations were limited to the short and intermediate terms.

Evidence for Complicated Urinary and Intra-abdominal Infections (cUTI/cIAI)

Recarbrio was studied for complicated urinary tract infections and intra-abdominal infections in limited randomized controlled trials. Research examined both clinical response and microbiological response (changes in bacteria counts). A key limitation is that many study patients had infections already susceptible to the core antibiotic component. This means the research provided limited information to fully assess the component's role in infections caused by highly resistant bacteria in this population. Evidence quality varies across studies for these two indications.

Research Gaps and Defined Populations

For patients with highly resistant infections and limited treatment options, research utilized only small, descriptive trials. The certainty remains low for this setting due to the small sample size and descriptive nature of the study design. Overall, the research do not include data from children, pregnant women, or other specific groups with complex comorbidities. Data for certain groups remain insufficient.

Common questions about Recarbrio (FAQ)

Q: How long does a course of Recarbrio treatment typically last?

Official product information states that the recommended duration of treatment with Recarbrio typically lasts between 4 and 14 days. The specific duration of treatment is determined by the healthcare provider, based on the type and severity of the patient's specific infection and their clinical response.

Q: How is the dose of Recarbrio adjusted for patients with kidney problems?

Dose adjustment is required for adult patients who have reduced kidney function, as the components of Recarbrio are primarily cleared through the kidneys. The specific dose and schedule are determined based on the patient's degree of renal impairment. For patients receiving hemodialysis, the official recommendation is that the reduced dose should be given immediately after the dialysis session.

Q: Can Recarbrio be used by pregnant or breastfeeding women?

Insufficient data is available on the use of this medicine in pregnant women to determine drug-associated risk. Regulatory information states that the medicine should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Imipenem and Cilastatin pass into human milk in low amounts. For breastfeeding mothers, the decision to continue or discontinue must take into account the importance of the medicine to the mother.

Q: How long does it take for the IV infusion of Recarbrio to be fully administered?

According to the official prescribing information, each dose of Recarbrio is prepared as a solution and must be delivered as an intravenous (IV) infusion over a period of 30 minutes. This timing aligns with the administration instructions provided in the regulatory product information.

Q: Does Recarbrio have an official indication for use in COVID-19 related infections?

Recarbrio's official indications, according to regulatory bodies, are for treating serious bacterial infections, including Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia (HABP/VABP), and specific complicated urinary and intra-abdominal infections. The official prescribing information does not list any indication for use in infections specifically related to COVID-19.

Q: Is a patient required to have bloodwork done while taking Recarbrio?

Official product information notes that changes, such as increases in liver enzymes, are common findings in studies. Furthermore, monitoring kidney function is specifically advised for patients with compromised kidney function. Official information supports the need for clinical monitoring, especially concerning kidney and liver function, which often involves blood tests.

How to Store and Dispose of Recarbrio

The storage of Recarbrio (imipenem, cilastatin, and relebactam) must strictly follow official labeling requirements to maintain potency.

Storage Conditions

Dry Powder Vials must be stored at controlled room temperature, specifically between 20 C to 25 C (68 F to 77 F). The vials should be kept in the original outer carton to ensure protection from light. This medicine must be stored out of the sight and reach of children.

Prepared Solution has limited stability. The solution must not be frozen. If refrigerated at 2 C to 8 C, it is stable for up to 24 hours. If kept at room temperature (up to 30 C), it should be used within 2 hours.

Disposal Instructions

Unused or expired Recarbrio must be disposed of according to local regulations. The medicine must not be disposed of via wastewater or household trash; consult a pharmacist for guidance on proper pharmaceutical waste disposal.